0001725160-21-000008.txt : 20210106
0001725160-21-000008.hdr.sgml : 20210106
20210106202541
ACCESSION NUMBER: 0001725160-21-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210104
FILED AS OF DATE: 20210106
DATE AS OF CHANGE: 20210106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SUN ANTHONY Y
CENTRAL INDEX KEY: 0001377952
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 21512596
MAIL ADDRESS:
STREET 1: C/O AISLING CAPITAL
STREET 2: 888 SEVENTH AVENUE, 30TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wf-form4_160998272301109.xml
FORM 4
X0306
4
2021-01-04
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001377952
SUN ANTHONY Y
C/O ZENTALIS PHARMACEUTICALS, INC.
530 SEVENTH AVENUE, SUITE 2201
NEW YORK
NY
10018
1
1
0
0
President & CEO
Common Stock
2020-11-22
5
G
0
E
213600
0
D
1804005
D
Common Stock
2020-11-22
5
G
0
E
213600
0
A
213600
I
See Footnote
Common Stock
2021-01-04
4
S
0
5418
50.4668
D
1798587
D
Common Stock
2021-01-04
4
S
0
3951
51.4056
D
1794636
D
Common Stock
2021-01-04
4
S
0
10612
52.4741
D
1784024
D
Common Stock
2021-01-04
4
S
0
6813
53.0632
D
1777211
D
Common Stock
974302
I
By Essex Group International, LLC
Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.805. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.83 to $51.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.84 to $52.82. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.85 to $53.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Anthony Y. Sun
2021-01-06